van der Merwe Johan, Casselman Filip, Stockman Bernard, Vermeulen Yvette, Degrieck Ivan, Van Praet Frank
Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium.
Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium. Electronic correspondence:
J Heart Valve Dis. 2017 Mar;26(2):124-129.
The study aim was to present details of the perioperative and long-term outcomes of redo-endoscopic port access surgery (REPAS) for late atrioventricular valve disease (AVVD) in orthotopic cardiac transplant (OCT) patients.
Between February 2004 and October 2015, REPAS was performed for late AVVD in seven consecutive OCT patients (mean age 57.9 ± 17.2 years; EuroSCORE II 21.2 ± 14.7%) at the authors' institution. The mean OCT-REPAS time interval was 7.8 ± 4.6 years (range: 1.3-13.8 years). NYHA class III or IV symptoms were present in four patients (57%). The mean left ventricular ejection fraction was 52.9 ± 3.9%, and surgical indications included severe mitral valve (MV) and tricuspid valve (TV) regurgitation in three patients (44%) and six patients (86%), respectively. Etiological factors included endomyocardial biopsy trauma (n = 6; 86%), degenerative disease (n = 2; 29%), and fungal endocarditis (n = 1; 14%).
Procedures performed included MV repair (n = 3; 43%) and TV replacement (n = 3; 43%). There were no sternotomy conversions or revisions for any cause. The mean cardiopulmonary bypass and ischemic times were 178.4 ± 48.6 min and 118.3 ± 39.5 min, respectively. In-hospital morbidities included hospital-acquired pneumonia (n = 2; 29%). There were no wound infections or 30-day mortalities. The mean duration of hospitalization was 18.3 ± 11.0 days. A mean of 29.2 ± 45.6 patient-months (total 204.3 patient-months) was available for long-term clinical and echocardiographic analysis (n = 7; 100% complete). No MV or TV reinterventions were required. NYHA class ≤II was achieved in five patients (71%). No patient presented with residual MV regurgitation greater than grade I.
REPAS for late AVVD in OCT patients is a safe and durable procedure with favorable technique-related mortality, in-hospital morbidity, and long-term cardiac-specific outcomes at experienced centers. The present technique provided an attractive benchmark against which emerging percutaneous interventions may be measured, and earlier referral of patients should be considered.
本研究旨在介绍原位心脏移植(OCT)患者晚期房室瓣疾病(AVVD)再次内镜下端口入路手术(REPAS)的围手术期及长期结果细节。
2004年2月至2015年10月期间,作者所在机构对7例连续的OCT患者(平均年龄57.9±17.2岁;欧洲心脏手术风险评估系统II 21.2±14.7%)进行了晚期AVVD的REPAS手术。OCT与REPAS的平均时间间隔为7.8±4.6年(范围:1.3 - 13.8年)。4例患者(57%)存在纽约心脏协会(NYHA)III或IV级症状。平均左心室射血分数为52.9±3.9%,手术指征分别包括3例患者(44%)的严重二尖瓣(MV)反流和6例患者(86%)的严重三尖瓣(TV)反流。病因包括心内膜活检创伤(n = 6;86%)、退行性疾病(n = 2;29%)和真菌性心内膜炎(n = 1;14%)。
实施的手术包括MV修复(n = 3;43%)和TV置换(n = 3;43%)。未因任何原因进行胸骨切开术转换或修正。平均体外循环时间和缺血时间分别为178.4±48.6分钟和118.3±39.5分钟。住院期间的并发症包括医院获得性肺炎(n = 2;29%)。无伤口感染或30天死亡率。平均住院时间为18.3±11.0天。平均有29.2±45.6患者 - 月(总计204.3患者 - 月)可用于长期临床和超声心动图分析(n = 7;100%完整)。无需进行MV或TV再次干预。5例患者(71%)达到NYHA≤II级。无患者出现大于I级的残余MV反流。
在经验丰富的中心,OCT患者晚期AVVD的REPAS是一种安全且持久的手术,在技术相关死亡率、住院期间并发症及长期心脏特异性结果方面表现良好。本技术提供了一个有吸引力的基准,可用于衡量新兴的经皮介入治疗,并且应考虑更早地转诊患者。